Efficacy of a New Class of
Agents (Glucosamine Hydrochloride and Chondroitin Sulfate) in The
Treatment of a Osteoarthritis of the Knee
Efficacy of a New Class of Agents
(Glucosamine Hydrochloride and Chondroitin Sulfate) in The Treatment of
a Osteoarthritis of the Knee
Amal M Das, Jr., MD, Hendsonville, NC, Jennifer Eitel, Tarek Hammad, MD,
Introduction: NSAIDS are the most popular drug for the treatment of
osteoarthritis of the knee. They are safe and effective. However they
are not entirely without side effects. Some NSAIDS inhibit
glycosaminoglycan synthesis and are thus postulated to accelerate
osteoarthritis. The agents studied herein have no known side effects and
have been shown to accelerate glycosaminoglycan synthesis. This is the
first North American study the efficacy of these agents.
Methods: A randomized double-blind placebo-controlled clinical trial of
93 patients with Kellgren and Lawrence grade II, III and IV
osteoarthritis of the knee is presented. The intervention group received
glucosamine 1000 mg and chondroitin sulfate 800 mg. PO BID. The
Lesquesne scale of osteoarthritis of the knee (IS10 was the primary
outcomes study used.
Results: The ISK improved from 10.2 (0.4) to 7.4 (0.6) in die
intervention group and 10.4 (0.4) to 9.0 (0.6) in the placebo group. The
difference in improvement between the two groups (3.2 for intervention
and I.4 for placebo) is significant (p=0.03). Twenty-eight percent (28%)
of the placebo group responded compared to 52% of the intervention group
(p=0.04). There was also a significant drop in the pain medication
requirement in the intervention group. 19% of the placebo group and 17%
of the intervention group suffered adverse reactions.
Discussion and Conclusion: The agents studied are effective for the
treatment of pain and loss of function associated with osteoarthritis of
the knee. They have no known side effects. Other studies have suggested
that they may be disease-modifying agents.
Source: American Association of Hip and Knee Surgeons; Eighth Annual
Fall Meeting. November 6 - 8, 1998. Dallas/Fort Worth Hilton. Executive
Conference Center, paper #18. To be published in Military Medicine,
February, 1999 issue.